Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia

JAMA

Volumn 301, Issue 4, 2009, Pages 393-403

  Yang, Jun J ^a   Cheng, ^a   Yang, Wenjian ^a   Pei, Deqing ^a   Cao, Xueyuan ^a   Fan, Yiping ^a   Pounds, Stanley B ^a   Neale, Geoffrey ^a   Trevino, Lisa R ^a   French, Deborah ^a   Campana, Dario ^a   Downing, James R ^a   Evans, William E ^a   Pui, Ching Hon ^a   Devidas, Meenakshi ^b   Bowman, W P ^c   Camitta, Bruce M ^d   Willman, Cheryl L ^e   Davies, Stella M ^f   Borowitz, Michael J ^g   Carroll, William L ^h   Hunger, Stephen P ⁱ   Relling, Mary V ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Children's Medical Center   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g DEPARTMENT OF PATHOLOGY   (United States)

^h NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MERCAPTOPURINE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG DISPOSITION; FEMALE; FLOW CYTOMETRY; GENE LOCUS; GENETIC VARIABILITY; GENOME; GENOME ANALYSIS; GENOTYPE; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION STUDY; ADOLESCENT; CHILD; FOLLOW UP; GENE LINKAGE DISEQUILIBRIUM; GENETICS; INFANT; METABOLISM; MUTATION; PHENOTYPE; PRESCHOOL CHILD; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; ETOPOSIDE; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENOTYPE; GERM-LINE MUTATION; HUMANS; INFANT; LINEAR MODELS; LINKAGE DISEQUILIBRIUM; MALE; METHOTREXATE; NEOPLASM, RESIDUAL; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 59249100224     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.7     Document Type: Article

References (65)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178.
2. Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 2007;6(2):149-165.
3. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998; 352(9142):1731-1738.
4. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using realtime quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771-782.
5. Szczepański T, Orfão A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol. 2001;2(7): 409-417.
6. Cave H, van der Werff ten Bosch J, Suciu S, et al; European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med. 1998;339(9):591-598.
7. Borowitz MJ, Pullen DJ, Shuster JJ, et al; Children's Oncology Group study. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors: a Children's Oncology Group study. Leukemia. 2003; 17(8):1566-1572.
8. Coustan-Smith E, Sancho J, Hancock ML, etal. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000; 96(8):2691-2696.
9. Zhou J, Goldwasser MA, Li A, et al; Dana-Farber Cancer Institute ALL Consortium. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007; 110(5):1607-1611.
10. Carroll WL, Bhojwani D, Min DJ, Moskowitz N, Raetz EA. Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer. 2006;46(5):570-578.
11. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1(2):133-143.
12. Holleman A, den Boer ML, de Menezes RX, et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood. 2006;107(2):769-776.
13. LugthartS,CheokMH,den Boer ML, et al. Identification of genes associated with chemotherapy cross-resistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell. 2005;7(4): 375-386.
14. Schmidt S, Rainer J, Riml S, et al. Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia. Blood. 2006;107(5):2061-2069.
15. TissingWJ, den Boer ML, Meijerink JP, et al. Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood. 2007;109(9):3929-3935.
16. Davies SM, Borowitz MJ, Rosner GL, et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia (ALL): a report from the Children's Oncology Group. Blood. 2008;111(6):2984-2990.
17. Rocha JC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005;105(12):4752-4758.
18. Relling MV, Hancock ML, BoyettJM, Pui CH, Evans WE. Prognosticimportanceof6-mercaptopurinedose intensity in acute lymphoblastic leukemia. Blood. 1999;93(9):2817-2823.
19. Fleury I, Primeau M, Doreau A, et al. Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia. Am J Pharmacogenomics. 2004; 4(5):331-341.
20. Pui CH, Sandlund JT, Pei D, et al; Total Therapy Study XIIIB at St Jude Children's Research Hospital. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004; 104(9):2690-2696.
21. Pui CH, Relling MV, Sandlund JT, Downing JR,Campana D, Evans WE. Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol. 2004;83 (suppl 1):S124-S126.
22. Rabbee N, Speed TP. A genotype calling algorithm for Affymetrix SNP arrays. Bioinformatics. 2006;22(1):7-12.
23. Scheet P, Stephens M. A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet. 2006;78(4):629-644.
24. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661-678.
25. Willer CJ, SannaS, JacksonAU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40 (2):161-169.
26. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008;9(5):356-369.
27. Cheng C, Pounds SB, Boyett JM, Pei D, Kuo ML, Roussel MF. Statistical significance threshold criteria for analysis of microarray gene expression data. Stat Appl Genet Mol Biol. 2004;3:article36.
28. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728-1733.
29. Wacholder S, Chanock S, Garcia-Closas M, El GL, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96(6):434-442.
30. Hunter DJ, Kraft P. Drinking from the fire hose- statistical issues in genomewide association studies. N Engl J Med. 2007;357(5):436-439.
31. SamaniNJ, ErdmannJ, Hall AS, et al; WTCCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. N Engl J Med.2007;357(5):443-453.
32. Richards JB, Rivadeneira F, Inouye M, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet. 2008; 371(9623):1505-1512.
33. Valdes AM, Loughlin J, Timms KM, et al. Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis. Am J Hum Genet. 2008;82(6):1231-1240.
34. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
35. Kishi S, YangW, Boureau B, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood. 2004;103(1):67-72.
36. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, Korzekwa KR. O-demethylation of epi-podophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994;45(2):352-358.
37. Leu BL, Huang JD. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol. 1995;35(5):432-436.
38. Yates CR, Chang C, Kearbey JD, et al. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003;20(11):1794-1803.
39. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther. 1999;66(6):589-593.
40. PlasschaertSL, Groninger E, Boezen M, et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther. 2004;76(3):220-229.
41. Lewis AD, Lau DH, Duran GE, Wolf CR, Sikic BI. Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer Res. 1992; 52(16):4379-4384.
42. van Asperen J, van Tellingen O, Beijnen JH. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos. 2000;28(3):264-267.
43. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest. 2005;115(1):110-117.
44. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is adeterminant of antileukemic effects in vivo: a rationale for high-dose methotrexate. J Clin Invest. 1996;97(1):73-80.
45. Bleyer WA, Nelson JA, Kamen BA. Accumulation of methotrexate in systemic tissues after intrathecal administration. J Pediatr Hematol Oncol. 1997;19(6):530-532.
46. Bostrom BC, Erdmann GR, Kamen BA. Systemic methotrexate exposure is greater after intrathecal than after oral administration. J Pediatr Hematol Oncol. 2003;25(2):114-117.
47. Conter V, Arico M, Valsecchi MG, et al; Associazione Italiana di Ematologia ed Oncologia Pediatrica. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt- Munster-based intensive chemotherapy. J Clin Oncol. 1995;13(10):2497- 2502.
48. Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007;109(10):4151-4157.
49. Sorich MJ, Pottier N, Pei D, et al. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med. 2008;5(4):e83.
50. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007;109(3):926-935.
51. Coustan-Smith E, Behm FG, SanchezJ, et al. Im- munological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351(9102):550-554.
52. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA. 2005;293 (12):1485-1489.
53. Budagian V, Bulanova E, Paus R, BulfonePaus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 2006;17(4):259-280.
54. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001; 97(1):14-32.
55. Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood. 2000;95(2):610-618.
56. Cario G, Izraeli S, Teichert A, et al. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. J Clin Oncol. 2007;25(30):4813-4820.
57. Zhang XJ, Yan KL, Wang ZM, et al. Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. J Invest Dermatol. 2007;127(11):2544- 2551.
58. Carroll WL. Race and outcome in childhood acute lymphoblastic leukemia. JAMA. 2003;290(15): 2061-2063.
59. Kadan-Lottick NS, Ness KK, BhatiaS, Gurney JG. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA. 2003;290 (15):2008-2014.
60. Pui CH, Sandlund JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA. 2003;290(15):2001-2007.
61. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904-909.
62. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358(10): 999-1008.
63. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353(9154): 717-719.
64. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19(8):2293-2301.
65. Malo N, Libiger O, Schork NJ. Accommodating linkage disequilibrium in genetic-association analyses via ridge regression. Am J Hum Genet. 2008;82(2):375-385.